Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers

被引:154
作者
Lubasch, A
Keller, I
Borner, K
Koeppe, P
Lode, H
机构
[1] Free Univ Berlin, Dept Chest & Infect Dis, Chest Hosp Heckeshorn, D-14109 Berlin, Germany
[2] Free Univ Berlin, Benjamin Franklin Hosp, Dept Phys Med, D-14109 Berlin, Germany
[3] Inst Clin Chem & Pathobiochem, Berlin, Germany
关键词
D O I
10.1128/AAC.44.10.2600-2603.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In an open, randomized, six-period crossover study, the pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin were compared after a single oral dose in 12 healthy volunteers (6 men and 6 women). The volunteers received 250 mg of ciprofloxacin, 400 mg of gatifloxacin, 600 mg of grepafloxacin, 500 mg of levofloxacin, 400 mg of moxifloxacin, and 200 mg of trovafloxacin. The concentrations of the six fluoroquinolones in serum and urine were measured by a validated high-performance liquid chromatography method. Blood and urine samples were collected before and at different time points up to 48 h after medication. Levofloxacin had the highest peak concentration (C-max, in micrograms per milliliter) (6.21 +/- 1.34), followed by moxifloxacin (4.34 +/- 1.61) and gatifloxacin (3.42 +/- 0.74). Elimination half-lives ranged from 12.12 +/- 3.93 h (grepafloxacin) to 5.37 +/- 0.82 h (ciprofloxacin). The total areas under the curve (AUC(tot), in microgram-hours per milliliter) for levofloxacin (44.8 +/- 4.4), moxifloxacin (39.3 +/- 5.35), and gatifloxacin (30 +/- 3.8) were significantly higher than that for ciprafloxacin (5.75 +/- 1.25). Calculated from a normalized dose of 200 mg, the highest C(max)s (in micrograms per milliliter) were observed for levofloxacin (2.48 +/- 0.53), followed by moxifloxacin (2.17 +/- 0.81) and trovafloxacin (2.09 +/- 0.58). The highest AUC(tot) (in microgram-hours per milliliter) for a 200-mg dose were observed for moxifloxacin (19.7 +/- 2.67) and trovafloxacin (19.5 +/- 3.1); the lowest was observed for ciprofloxacin (4.6 +/- 1.0). No serious adverse event was observed during the study period. The five recently developed fluoroquinolones (gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin) showed greater bioavailability, longer half-lives, and higher C(max)s than ciprofloxacin.
引用
收藏
页码:2600 / 2603
页数:4
相关论文
共 18 条
[1]  
Andriole VT, 1998, QUINOLONES, 2ND EDITION, P417
[2]  
Bergan T, 1998, QUINOLONES, 2ND EDITION, P143
[3]  
BORNER K, 1986, J CLIN CHEM CLIN BIO, V24, P325
[4]   CHROMATOGRAPHIC DETERMINATION OF OFLOXACIN IN BODY-FLUIDS [J].
BORNER, K ;
HARTWIG, H ;
LODE, H ;
HOFFKEN, G .
FRESENIUS ZEITSCHRIFT FUR ANALYTISCHE CHEMIE, 1986, 324 (3-4) :355-355
[5]   Determination of trovafloxacin in human body fluids by high-performance liquid chromatography [J].
Borner, K ;
Hartwig, H ;
Lode, H .
JOURNAL OF CHROMATOGRAPHY A, 1999, 846 (1-2) :175-180
[6]   PHARMACOKINETICS OF CIPROFLOXACIN IN HEALTHY-VOLUNTEERS AFTER ORAL AND INTRAVENOUS ADMINISTRATION [J].
BORNER, K ;
HOFFKEN, G ;
LODE, H ;
KOEPPE, P ;
PRINZING, C ;
GLATZEL, P ;
WILEY, R ;
OLSCHEWSKI, P ;
SIEVERS, B ;
REINITZ, D .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1986, 5 (02) :179-186
[7]   Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects [J].
Chien, SC ;
Chow, AT ;
Natarajan, J ;
Williams, RR ;
Wong, FA ;
Rogge, MC ;
Nayak, RK .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1562-1565
[8]   Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses [J].
Chien, SC ;
Rogge, MC ;
Gisclon, LG ;
Curtin, C ;
Wong, F ;
Natarajan, J ;
Williams, RR ;
Fowler, CL ;
Cheung, WK ;
Chow, AT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2256-2260
[9]   PHARMACOKINETICS AND TISSUE PENETRATION OF THE NEW FLUOROQUINOLONE GREPAFLOXACIN [J].
CHILD, J ;
ANDREWS, JM ;
WISE, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) :513-515
[10]   Pharmacokinetics of grepafloxacin [J].
Efthymiopoulos, C .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 :35-43